Belite Bio CFO Chuang Hao-Yuan sells $12.8 million in company ADSs

Chuang Hao-Yuan, CFO and Director at BELITE BIO, INC (BLTE), divested 62,395 American depositary shares, valued at roughly $12.8 million, on September 4 and September 8, 2026. The shares were purchased at a price range of $180.1597 to $198.0454 per ADS through a Rule 10b5-1 trading plan initiated in December 2025. Post the sale, Chuang retained 26,038 ADSs.

BELITE BIO shares are nearing their 52-week high of $200, having surged 176% in the past year. Despite being in overbought territory, the stock appears undervalued relative to its Fair Value. BELITE BIO has filed a New Drug Application with Japan’s Ministry of Health, Labour, and Welfare for tinlarebant, aimed at treating Stargardt disease type 1 under Sakigake Designation for expedited review.

This has been met with bullish sentiment, with investment firms raising their price targets for the company's stock.